BioMedNewsBreaks

ThursdayJul 30, 2026 12:58 pm

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Closes CAD$5 Million Private Placement to Advance Oncology Programs

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced the closing of its previously announced non-brokered private placement with Sorbie Bornholm LP and Sorbie Investments LLP, representing a notional subscription amount of approximately CAD$5 million. The financing included the issuance of 7.94 million units at a notional price of CAD$0.63 per unit, with each unit consisting of one common share and one warrant exercisable at CAD$0.77 for three years. The proceeds will be made available to the company through an 18-month sharing arrangement tied to the volume-weighted…

Continue Reading

ThursdayJul 30, 2026 12:23 pm

BioMedNewsBreaks — Earth Science Tech Inc.’s (ETST) Vertical Integration Drives Revenue Growth, Product Expansion

Earth Science Tech (OTC: ETST) is leveraging a diversified, vertically integrated business model spanning pharmaceuticals, telemedicine, retail and real estate. Through subsidiaries including Peak Curative, RxCompound and Mister Meds, the company connects telemedicine consultations, compounding pharmacies and medication fulfillment within an end-to-end healthcare ecosystem. Its MOCTeledoc platform also provides B2B technology and clinical staffing solutions, allowing ETST to generate revenue by supporting other digital health companies while expanding its own reach. The integrated model supports product development and diversification, contributing to fiscal 2026 revenue growth of 8%, alongside increases in gross profit and net income. To view the full article, visit https://ibn.fm/I1F0R…

Continue Reading

ThursdayJul 30, 2026 11:54 am

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Highlights Growing Clinical Evidence Supporting Nu.Q NETs Test 

VolitionRx Limited (NYSE American: VNRX) highlighted a growing body of clinical and scientific evidence supporting its Nu.Q NETs assay as a biomarker for sepsis and other diseases associated with NETosis, while releasing an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter. The company said multiple studies have shown its Nu.Q H3.1 test can distinguish sepsis from non-infectious inflammation, correlate with disease severity and provide strong prognostic value for outcomes including organ failure and mortality. Volition said most of the supporting research has been peer reviewed and published, with experts noting the consistency of findings across multiple countries and patient populations. The company believes its low-cost nucleosome quantification technology…

Continue Reading

WednesdayJul 29, 2026 3:54 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Targets $3 Billion Cartilage Repair Market with Cell-Free Gelrin C

Regentis Biomaterials (NYSE American: RGNT) is positioning its Gelrin C hydrogel as a practical regenerative medicine solution for cartilage damage that could help address the substantial clinical and economic burden associated with knee osteoarthritis (“OA”). Gelrin C is a cell-free, off-the-shelf hydrogel administered in a single 10-minute procedure, designed to support cartilage regeneration while avoiding the multiple surgeries, specialized laboratory processing and higher costs associated with some cell-based therapies. With approximately 470,000 knee cartilage repair procedures performed annually in the U.S., representing an estimated $3 billion market, the company believes Gelrin C could offer a more scalable approach that fits existing surgical…

Continue Reading

WednesdayJul 29, 2026 3:26 pm

BioMedNewsBreaks — MindBio Therapeutics Corp.’s (CSE: MBIO) (OTCQB: MBQIF) Edge AI Kiosks Target Rapid, Scalable Impairment Screening

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) has completed and delivered its first Edge AI Intoxication and Fatigue Detection Kiosk prototypes, advancing its efforts to commercialize voice-based impairment detection technology for workplace safety applications. The kiosks use artificial intelligence to analyze short voice samples for more than 140 acoustic markers associated with potential alcohol, drug or fatigue-related impairment, with models trained on more than 50 million data points. The prototypes are now entering testing, validation and data-analysis phases involving industry participants, speech specialists and software engineers as the…

Continue Reading

WednesdayJul 29, 2026 9:00 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platforms

VERAXA Biotech (NASDAQ: VRXA) announced an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 covering its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. Pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047. The company said its BiTAC platform is designed to improve the selectivity and…

Continue Reading

MondayJul 27, 2026 3:30 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Executive Outlines Lucid-MS Development Strategy and Commercial Growth Plans

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, was featured in a recent episode of the BioMedWire Podcast. During the program, Executive Co-Chairman and Co-Founder Anthony Durkacz discussed the company’s strategy for advancing Lucid-MS, its lead drug candidate for multiple sclerosis, as well as the commercial opportunity surrounding its unbuzzd product. Durkacz highlighted Lucid-MS’s goal of addressing mobility damage associated with MS and noted that the company has filed an investigational new drug application for a Phase 2 clinical trial,…

Continue Reading

MondayJul 27, 2026 2:55 pm

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) Moves Lead Oncology Candidate Toward Future Clinical Studies

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is advancing the development of its lead oncology candidate, ONC010, a PNKP inhibitor designed to disrupt cancer cells’ DNA repair mechanisms and potentially address treatment resistance. The company recently advanced kilogram-scale manufacturing of a key precursor used to produce ONC010’s active pharmaceutical ingredient, supporting future formulation development, GMP production and clinical studies. Onco-Innovations also signed a letter of intent with Nanosoft Polymers to advance polymer development, drug delivery optimization and formulation work, while engagements with Nucro-Technics and Avance Clinical support bioanalytical development and clinical…

Continue Reading

MondayJul 27, 2026 2:17 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Builds on End-to-End Platform Connecting Telemedicine, Pharmacy and Fulfillment

Earth Science Tech (OTC: ETST) recently announced fiscal year 2026 results for the year ended March 31, 2026, highlighting growth across key financial metrics as it continues to operate its diversified holdings model spanning healthcare, pharmaceuticals, telemedicine, real estate and consumer businesses. Revenue increased 8% to $35.7 million, gross profit rose 5% to $25.5 million, net income grew 11% to $3.6 million, and total assets increased 27% to $9 million. CEO Giorgio R. Saumat attributed the results to ETST’s efforts to fully integrate the patient experience across telemedicine to pharmacy to fulfillment. To view the full article, visit https://ibn.fm/mY8eX About Earth Science Tech…

Continue Reading

MondayJul 27, 2026 11:46 am

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures 

VERAXA Biotech (NASDAQ: VRXA) announced that shareholders overwhelmingly approved all proposals presented at its Extraordinary General Meeting, with more than 99.94% of votes cast in favor and 72.20% of the company's outstanding share capital represented. The approved measures include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through Dec. 31, 2030 and an increase in the maximum size of the board of directors from five to seven members. The company said the enhanced corporate and financing framework is intended to support its long-term growth strategy by providing greater flexibility for potential acquisitions, strategic collaborations, investment projects, capital…

Continue Reading